HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy.

Abstract
Smith-Lemli-Opitz syndrome (SLOS) is a genetic syndrome caused by mutations in the 3beta-hydroxysterol Delta(7)-reductase gene (DHCR7). SLOS patients have decreased cholesterol and increased 7-dehydrocholesterol (7-DHC) levels. Dietary cholesterol supplementation improves systemic biochemical abnormalities; however, because of the blood-brain barrier, the central nervous system (CNS) is not treated. Simvastatin therapy has been proposed as a means to treat the CNS. Mice homozygous for a null disruption of Dhcr7, Dhcr7(Delta3-5/Delta3-5), die soon after birth, thus they cannot be used to study postnatal development or therapy. To circumvent this problem, we produced a hypomorphic SLOS mouse model by introducing a mutation corresponding to DHCR7(T93M). Both Dhcr7(T93M/T93M) and Dhcr7(Delta3-5/T93M) mice are viable. Phenotypic findings in Dhcr7(T93M/Delta3-5) mice include CNS ventricular dilatation and two to three syndactyly. Biochemically, both Dhcr7(T93M/T93M) and Dhcr7(T93M/Delta3-5) mice have elevated tissue 7-DHC levels; however, the biochemical defect improved with age. This has not been observed in human patients, and is due to elevated Dhcr7 expression in mouse tissues. Dietary cholesterol therapy improved sterol profiles in peripheral, but not CNS tissues. However, treatment of Dhcr7(T93M/Delta3-5) mice with simvastatin decreased 7-DHC levels in both peripheral and brain tissues. Expression of Dhcr7 increased in Dhcr7(T93M/Delta3-5) tissues after simvastatin therapy, consistent with the hypothesis that simvastatin therapy improves the biochemical phenotype by increasing the expression of a Dhcr7 allele with residual enzymatic activity. We conclude that simvastatin treatment is efficacious in improving the SLOS-associated sterol abnormality found in the brain, and thus has the potential to be an effective therapeutic intervention for behavioral and learning problems associated with SLOS.
AuthorsLina S Correa-Cerro, Christopher A Wassif, Lisa Kratz, Georgina F Miller, Jeeva P Munasinghe, Alexander Grinberg, Steven J Fliesler, Forbes D Porter
JournalHuman molecular genetics (Hum Mol Genet) Vol. 15 Issue 6 Pg. 839-51 (Mar 15 2006) ISSN: 0964-6906 [Print] England
PMID16446309 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Threonine
  • Methionine
  • Simvastatin
  • Oxidoreductases Acting on CH-CH Group Donors
  • 7-dehydrocholesterol reductase
Topics
  • 3T3 Cells
  • Alleles
  • Amino Acid Substitution (genetics)
  • Animals
  • Cells, Cultured
  • Crosses, Genetic
  • Disease Models, Animal
  • Embryonic Stem Cells (transplantation)
  • Female
  • Magnetic Resonance Spectroscopy
  • Methionine (genetics)
  • Mice
  • Mice, Inbred C57BL
  • Mutagenesis, Site-Directed
  • Oxidoreductases Acting on CH-CH Group Donors (genetics)
  • Phenotype
  • Simvastatin (therapeutic use)
  • Smith-Lemli-Opitz Syndrome (drug therapy, enzymology, genetics)
  • Threonine (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: